Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Allergy Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Allergy Other
    Inhaled Ciclesonide Improves Asthma Control: Presented at ACAAI - (DGDispatch)
    Efficacy of Aqueous Triamcinolone Acetonide in Allergic Rhinitis Not Affected by Gender: Presented at ACAAI - (DGDispatch)
    FDA Approves a C1-Esterase Inhibitor for Abdominal Attacks, Facial Swelling Associated With HAE - (DGNews)
    FDA Approves Bepotastine Besilate Solution for Ocular Itching Associated With Allergies - (DGNews)
    FDA Approves Levocetirizine Dihydrochloride for Paediatric Nasal Allergies - (DGNews)

    News archive

     Recent webcasts/CME - Allergy Other
    • Alpha1-Antitrypsin Deficiency: Incidence, Screening, and Management
    • Early Detection of Alpha1-Antitrypsin (AAT) Deficiency Helps Prevent Disease Progression
    • Advances in Hereditary Angioedema Treatment: Considerations, Criteria & the New Therapy Options for Treatment & Prevention of HAE Attacks
      Sublingual Immunotherapy (SLIT) for Allergic Rhinitis The Latest Evidence
      Update in Hereditary Angioedema: A Disease in Rapid Evolution

      Webcasts/CME archive

       Recent cases - Allergy Other
        Gallbladder Edema in Type 1 Diabetic Patient due to Delayed-type Insulin Allergy
        Anaphylaxis Following Intravenous Fluorescein Angiography in a Vitreoretinal Clinic: Report of 4 Cases
        Acute Allergic Reaction due to Milk Proteins Contaminating Lactose Added to Corticosteroid for Injection
        Acute Generalized Exanthematous Pustulosis (AGEP) Triggered by a Spider Bite
        Anaphylactic Reaction to Camomile Tea

        Cases archive
          




        my personal edition > allergy other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Fexofenadine (Allegra) Safe and Efficacious in Children With Seasonal Allergic Rhinitis: Presented at AAAAI

        By Bonnie Darves

        SAN FRANCISCO, CA -- March 24, 2004 -- The antihistamine fexofenadine (Allegra), appears to be both safe and effective in the treatment of seasonal allergic rhinitis (SAR) in young children age 6 through 11, according to results of a large study presented here at the American Academy of Allergy, Asthma & Immunology Annual meeting.

        "[Fexofenadine] was effective in reducing the symptoms in this population -- and it was safe and well tolerated," said study co-author Allan Puterman, MD, University of Cape Town, South Africa. He added that although the drug has not yet been approved for use in this population in the United States, because little safety data has been available, it has now been registered in South Africa and other countries.

        The placebo-controlled, double blind study of 579 children, conducted in 40 centres in the Southern Hemisphere, involved 303 patients with a 1-year history of SAR, predominantly from grass allergy (>93%). Following positive skin-prick test results, patients were randomised to receive either 30 mg BID of fexofenadine or placebo for 2 weeks. They were evaluated for efficacy based on change in 12-hour total symptom scores from baseline.

        Fexofenadine treatment significantly improved total symptom scores compared to placebo (P = .0178) and was well tolerated. Dr. Puterman said that the Southern Hemisphere study, as well as a similar European study, used the same efficacy end points employed in previous adult trials and generated similar safety profiles, further validating the use of fexofenadine in children.

        "The drug is now approved for this younger population in Europe and South Africa, and it's likely the U.S. will follow," Dr. Puterman said.


        [Study Title: Pollen Aeroallergen Sensitization and Efficacy of Fexofenadine in Children From the Southern Hemisphere. Poster 826]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send